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Abstract
Background: Cystic fibrosis (CF) is an inherited disorder caused by mutations in the CF transmembrane
conductance regulator (CFTR) gene that promotes persistent lung infection and inflammation and progressive loss
of lung function. Patients with CF have increased lung lymphoid follicles (LFs) and B cell-activating factor of tumor
necrosis factor family (BAFF) that regulates B cell survival and maturation. A direct role for CFTR in B cell activation
and disease pathogenesis in CF remains unclear.
Methods: The number of LFs, BAFF+, TLR4+ and proliferation marker Ki67+ B cells in lung explants or resections
from subjects with CF and normal controls was quantified by immunostaining. The role of CFTR in B cell activation
and LF development was then examined in two independent cohorts of uninfected CFTR-deficient mice (Cftr −/−)
and wild type controls. The number of lung LFs, B cells and BAFF+, CXCR4+, immunoglobulin G+ B cells was
examined by immunostaining. Lung and splenocyte B cell activation marker and major histocompatibility complex
class II (MHC class II) expression was quantified by flow cytometry. Inflammatory cytokine levels were measured in
supernatants from isolated B cells from Cftr −/− and wild type mice stimulated in vitro with Pseudomonas aeruginosa
lipopolysaccharide (LPS).
Results: There was a significant increase in well-formed LFs in subjects with CF compared to normal controls.
Increased B cell activation and proliferation was observed in lung LFs from CF subjects as was quantified by a
significant increase in B cell BAFF, TLR4 and Ki67 expression. Uninfected Cftr −/− mice had increased lung LFs and
BAFF+ and CXCR4+ B cells compared to wild type controls. Lung B cells isolated from uninfected Cftr −/− mice
demonstrated increased MHC class II expression. In vitro, isolated B cells from Cftr −/− mice produced increased IL-6
when stimulated with LPS compared to wild type controls.
Conclusions: These data support a direct role for CFTR in B cell activation, proliferation and inflammatory cytokine
production that promotes lung LF follicle development in cystic fibrosis.
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Background
Cystic fibrosis (CF) is a monogenic autosomal recessive
disorder associated with significant morbidity and mor-
tality that affects approximately 1 in 3000 newborns in
the US. Despite significant advances in treatment, the
median predicted survival for a CF patient born between
2003 and 2007 is 37 years [1]. CF arises from mutations
in the CF transmembrane conductance regulator (CFTR)
that lead to impaired chloride and bicarbonate transport.
Impaired CFTR epithelial cell function in patients with
CF leads to viscous mucus, impaired mucociliary clear-
ance and airway colonization with pathogenic bacteria,
especially Pseudomonas aeruginosa (P. aeruginosa).
These changes in airway biology lead to progressive lung
damage and respiratory insufficiency. Recently, the iono-
cyte was identified as the main CFTR expressing epithelial
cell [2]. However, CFTR expression on both innate and
adaptive immune cells has been increasingly appreciated
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to contribute to immune dysfunction and disease patho-
genesis in CF.
The absence of normal CFTR expression on macro-
phages has been linked to increased inflammatory cyto-
kine production, altered TLR4 trafficking and impaired
resolution of infection and inflammation [3–5]. A direct
role for CFTR in macrophage function was confirmed
by siRNA knockdown of CFTR expression on human al-
veolar macrophages. Alveolar macrophages with silenced
CFTR had increased IL-8 secretion, increased NF-κB
phosphorylation and increased caveolin-1 expression [6].
The T helper 2 (Th2) skewing of CD4 lymphocytes from
both patients and Cftr −/− mice has been well described
[7, 8]. CFTR deficiency has also been linked to dimin-
ished regulatory CD4 T cell (Treg) effector function [9].
B cells are critical for adaptive immune responses and
express CFTR mRNA. Human B cells that lack CFTR
have impaired chloride conductance as is observed in
CFTR-deficient epithelial cells [10, 11]. B cell-activating
factor of tumor necrosis factor family (BAFF) is pro-
duced by B cells, T cells and myeloid lineage cells and
plays an important role in B cell survival and maturation
[12]. BAFF can bind to three receptors that are constitu-
tively expressed on B cells (BAFF-receptor, transmem-
brane activator and calcium modulator and cyclophilin
ligand interactor and B-cell maturation antigen). BAFF
is not produced by B cells at steady state but is induced
by antigen-activated helper T cells. BAFF produced by B
cells can work in both an autocrine and paracrine man-
ner [12–14]. The importance of BAFF in lung B cell de-
velopment and immunity was recently reinforced and
confirmed to be important in CF. Wild type and Cftr −/−
mice treated with a neutralizing antibody that blocks
BAFF resulted in B cell and lung CD4+ regulatory T cell
(Treg) depletion. Blockade of BAFF and resultant B cell
depletion increased the lung bacterial burden in both
wild type and CFTR deficient mice infected with P. aeru-
ginosa, although the bacterial load and lung resistance
was higher in the CFTR deficient mice [15]. BAFF has
been detected in bronchoalveolar lavage (BAL) fluid
from patients with CF and was most elevated in patients
infected with P. aeruginosa. BAFF was not detected in
BAL fluid from healthy controls [16]. BAFF was also
shown to be induced in the lungs of wild type mice in-
fected with P. aeruginosa [16].
Peribronchial lymphoid follicles (LFs) have been ob-
served in patients with CF and developed in wild type
mice in response to bacterial infection. Wild type
mice infected with P. aeruginosa had elevated levels
of lung tissue BAFF and B cell chemoattractants in-
cluding CXCL13 [16, 17]. Lung B cell BAFF expres-
sion has also been shown to correlate with LF
development in chronic obstructive pulmonary disease
(COPD) [13]. Lung BAFF and specifically autocrine B
cell BAFF production may contribute to the promo-
tion and persistence of airway inflammation as was
demonstrated in patients with COPD [13]. These
findings raise questions as to whether LF develop-
ment may contribute to CF lung pathology. The ob-
servation of increased lung BAFF and LFs has been
made in lung tissue from patients with CF that have
airway colonization with pathogenic bacteria and BAL
fluid and lung tissue from wild type mice infected
with P. aeruginosa [16, 17]. However, a direct role for
CFTR in B cell immune function has not been well
characterized.
Several murine Cftr −/− lines deficient in CFTR have
been developed and do not develop lung pathology in
the absence of direct exposure to pathogenic bacteria
[18]. However, age dependent increases in interstitial
macrophages and interstitial thickening have been ob-
served in lung tissue from uninfected Cftr −/− mice [19].
A different group examined uninfected Cftr −/− mice 16
to 20 weeks of age and also observed lung inflammatory
cell infiltration that was not present in wild type con-
trols. Interestingly, immunoglobulin chain genes were
the genes that were most overexpressed in lung tissue
from uninfected Cftr −/− mice versus wild type controls
in this study [20]. These changes in unchallenged mice
suggest that CFTR deficiency may contribute to lung in-
flammation in the absence of infection over time. Here,
we demonstrate a role for CFTR in the promotion of
tertiary lung LF development, B cell BAFF and CXCR4
expression and B cell inflammatory cytokine production
in the absence of infection.
Materials and methods
Human lung sections
Lung tissue sections from CF patients were obtained
from archival lung specimens from lung explants ob-
tained at the time of lung transplantation or wedge
resections/lobectomies performed for clinical indica-
tions. Normal lung tissue sections were identified by
a clinical expert (S.O.V.) from surgical tissue obtained
from patients without CF, bronchiectasis or other
underlying primary lung disease. The control group
was comprised of an uninvolved area of lung from a
subjects with malignancy (peripheral nerve sheath
tumor (n = 1), inflammatory myofibroblastic tumor
(n = 1), pleomorphic sarcoma (n = 1), pulmonary car-
cinoid tumor (n = 1), anaplastic large cell lymphoma
(n = 1)) and uninvolved lung tissue adjacent to an ap-
ical bleb (n = 5). The experimental protocol only used
archival lung tissue and was approved by the institu-
tional review board at Boston Children’s Hospital. Pa-
tient characteristics are described in Table 1. None of
the subjects included in the study were on CFTR
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modulator therapy at the time of lung tissue
sampling.
Murine Cftr −/− models
All studies were conducted in accordance with the In-
stitutional Animal Care and Use Committees of Boston
Children’s Hospital and Brigham and Women’s Hos-
pital/Harvard Medical School. The generation,
characterization and maintenance of the Cftrtm1UNC
mouse (Cftr −/−) congenic on C57BL/6 J background
has been previously described [21]. The first cohort in-
cluded Cftr −/− and C57BL/6 J control mice 18–20
weeks of age housed at Brigham and Women’s Hospital
(cohort 1). Lung tissue that was fixed with formalin and
embedded in paraffin was available from this cohort.
The second cohort included Cftrtm1UNC and C57BL/6 J
control mice between 43 and 59 weeks of age, which
were generously provided by Dr. Mitchell Drumm and
Case Western Reserve University CF Mouse Models
Core (cohort 2). These mice were euthanized with over-
dose of pentobarbital, and lung and splenic tissue har-
vested within 48 h of arrival at the Boston Children’s
Hospital animal facility. Briefly, after perfusion of the
right ventricle with PBS, one lung was isolated and re-
moved for isolation of mononuclear cells. The contra-
lateral lung was then inflated with and fixed in formalin
for immunohistochemistry as previously described [13].
Table 1 Patient demographics
Cystic fibrosis (n = 27) Controls (n = 10) p value
Age (yr) 15.9 ± 0.98 15.3 ± 0.65 0.71
Sex (M/F) 15/12 5/5 0.77




Body-mass index (kg/m2) 18.1 ± 2.2
Prebronchodilator FEV1 (% of predicted value) 33.0 ± 0.04
Pancreatic insufficiency (no.) 27/27
Airway colonization with:
Pseudomonas aeruginosa 19/25
Methicillin-resistant Staphylococcus aureus 8/25
Methicillin-sensitive Staphylocccus aureus 9/25











Pancreatic insufficiency (no.) 27/27
CF-related diabetes mellitus (no.) 13/27
CF-related liver disease (no.) 5/27
Non-tuberculous mycobacteria lung infection (no.) 1/21
Allergic bronchopulmonary aspergillosis (no.) 4/27
Immunoglobulin E (mg/dL) 278 ± 107.5
Plus-minus values indicate ± SEM
CF cystic fibrosis, CFTR cystic fibrosis transmembrane conductance regulator, F508del-CFTR delta 508 CFTR mutation, FEV1 forced expiratory volume in 1 s
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Characterization of pulmonary LFs using
immunofluorescence
Human cohort: Formalin-fixed and paraffin-embedded
(5 μm-thick) lung sections from explants or lung resec-
tions from patients with CF (n = 27) or normal lung tis-
sue obtained during surgical resections (n = 10) were
deparaffinized, and antigen retrieval was performed by
boiling the slides immersed in 0.01M sodium citrate
and 2mM citrate buffer (pH 6.0) in a microwave. To
identify human pulmonary LFs, lung sections were im-
munostained with: 1) murine anti-CD20 IgG conjugated
to Alexa-Cy5 IgG; 2) rat anti-BAFF IgG conjugated with
Alexa 488 F (ab’)2; and 3) rabbit anti-ki67 conjugated
with Alexa 546 IgG. All the primary antibodies were
purchased from Abcam (Cambridge, MA) and the sec-
ondary antibodies were purchased from Invitrogen.
Murine cohorts: Formalin-fixed and paraffin-embedded
sections (5 μm thick) of lung sections were obtained from
two cohorts of wild type and Cftr −/− mice housed at differ-
ent institutions and animal facilities (see above). Lung sec-
tions were incubated with rabbit anti-CD45R or murine
anti-CD20 to identify B cells and were additionally stained
with rat anti-BAFF, rabbit anti-IgG and goat anti-CXCR4
primary antibodies purchased from Abcam. Goat anti-rat
Alexa 488 F (ab’)2, goat anti-mouse Alexa Cy5 IgG and goat
anti-rabbit Alexa 546 IgG secondary antibodies were ob-
tained from Invitrogen. For TLR4 analysis, rabbit anti-
CD20 antibody (Abcam), mouse anti-TLR4 antibody
(Abcam) and goat anti-mouse IgG AlexaFluor-488 and goat
anti-rabbit AlexaFluor-546 secondary antibodies (Invitro-
gen) were used. Slides were quenched with Sudan black
and counterstained with 4′,6-diamidino-2-phenylindole
(DAPI) as previously described [13]. Lung sections were
also immuno-stained with the appropriate isotype- and
species-matched non-immune control antibodies.
Microscopy and image analysis
For each slide, a minimum of 20 randomly-selected high-
magnification fields were evaluated using a Leica epi-
fluorescence microscope (Leica Microsystems, Buffalo
Grove, IL) except in the case of TLR4 analysis where a
Nikon Eclipse 80i microscope (Melville, NY) was used. In
both human and murine cohorts, the number of LFs,
CD20- or CD45R-positive B cells, BAFF-, CXCR4-, IgG-,
TLR4- or Ki67-positive B cells were counted, and the data
were expressed as median number/tissue area. Lymphoid
follicles were defined as aggregates containing more than
40 mononuclear cells exhibiting the typical topographical
arrangement with centrally located B cells along with a
few follicular dendritic cells and CD4 and CD8 cells in the
periphery. LFs located within a clearly defined lymph node
capsule were excluded from analysis. Images of the immu-
nostained lung sections were captured and analyzed using
a confocal microscope (Olympus Corporation, Center
Valley, PA). Confocal micrographs were recorded under
fluorescence imaging mode in which cells were exposed to
488, 570, and 670 nm light attenuated by an acusto-
tunable optical filter. Tissue area was measured using
MetaMorph software (Molecular Devices, Sunnyvale, CA).
The area of the LFs was also measured using MetaMorph
software by drawing a region of interest around the per-
ipheries of the LFs between the B-cell-abundant areas and
areas in which there were few B-cells [13].
Lung and splenocyte mononuclear cell flow cytometry
Flow cytometry was performed on mononuclear cells iso-
lated from spleen and lung tissue from wild type and Cftr
−/− mice. Lungs and spleen were harvested and digested as
previously described [22]. Briefly, minced spleen tissue
was passed over nylon mesh filter and minced lung tissue
was digested with collagenase (Type IV, Worthington,
Lakewood, NJ) and DNAse I (Roche/Sigma) for 1 h at
37 °C with constant horizontal shaking to generate single
cell suspension as previously described [22]. After red cell
lysis, the single cell suspensions were incubated with puri-
fied rat anti-mouse CD16/CD32 (BD Biosciences, San
Diego, CA) to block Fcγ receptors for 30min at 4 °C in
flow cytometry buffer (PBS with 2.5% fetal bovine serum
albumin (Gibco/Thermo Fisher Scientific, Waltham, MA).
Cells were subsequently stained with optimal concentra-
tions of conjugated monoclonal antibodiess and their ap-
propriate isotype controls for 30min at 4 °C. Directly
conjugated fluorochrome antibodies were used including
anti-mouse PE-Cy7 CD19 antibody (Biolegend, San Diego,
CA), anti-mouse FITC MHC class II antibody (I-A/I-E,
BD Biosciences), anti-mouse PE CD86 antibody (BD Bio-
sciences), anti-mouse PE CD8α antibody (BD Biosciences),
anti-mouse PE CD4 antibody (BD Biosciences), anti-
mouse PE-Cy7 CD45 antibody (Thermo Fisher Scientific),
anti-mouse FITC CD3 antibody (BD Biosciences) and pro-
pidium iodide (Sigma Aldrich, St. Louis, MO). The cells
were then washed and analyzed using a FACS Canto II
flow cytometer (Becton Dickinson, San Jose, CA) and
Flow Jo software (Ashland, OR). After doublet exclusion,
propidium iodide staining was used to exclude dead cells.
Results are expressed as the median fluorescent intensity
(MFI) index. MFI index is the MFI with the tested anti-
body divided by the MFI of the appropriate isotype-
matched control antibody.
B cell functional assays
Untouched B cells were isolated from mononuclear sple-
nocyte cell suspensions from Cftr −/− and wild type mice
with mouse B cell Isolation Kit (Miltenyi Biotec, Au-
burn, CA) as per manufacturer’s instructions. 1 × 105 B
cells in Dulbecco’s Modified Eagle’s Medium (DMEM;
Life Technologies, Grand Island, NY) containing 10%
fetal bovine serum (Gibco/Thermo Fisher Scientific),
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100 IU/ml penicillin and 100 mg/ml penicillin/strepto-
mycin (Gibco/Thermo Fisher Scientific) were plated in
96-well plates and stimulated with media or 25 μg/ml
lipopolysaccharide (LPS, from Pseudomonas aeruginosa,
Sigma Aldrich) at 37 °C and 5% CO2 [23] Supernatants
were harvested at 48 h and stored at -80 °C until further
analysis. Murine IL-6 and IL-10 were measured in super-
natants by ELISA as per manufacturer’s instructions
(ThermoFisher Scientific).
Statistics
For pairwise comparisons, parametric and nonparametric
data were analyzed using two-sided Student’s t tests and
Mann-Whitney U tests, respectively. Bar graphs represent
mean and SEM, whereas boxes in box plots show the me-
dian values and 25th and 75th percentiles, and error bars
show the 10th and 90th percentiles. Correlation coeffi-
cients were calculated using the Pearson rank method. P
value less than or equal to 0.05 was considered statistically
significant. Analyses were performed using GraphPad
prism (GraphPad Software, San Diego, CA).
Results
Patient characteristics
Lung tissue sections were obtained from patients with
CF (n = 27) and normal controls (n = 10). The majority
of the CF lung tissue came from lung explants at the
time of transplantation. Age and gender matched con-
trols were also analyzed. Patient characteristics are listed
in Table 1. The majority of the patients had severe lung
disease as defined by forced expiratory volume in 1 s
(FEV1) percent predicted. The average FEV1 was 33.0%
predicted. 76.0% percent had airway colonization with P.
aeruginosa and 73.6% were homozygous for the
F508del-CFTR mutation. Reflective of the severity of the
patients in this cohort, BMI was reduced and all the pa-
tients were pancreatic insufficient. 48.1% of patients had
CF-related diabetes mellitus. The average age was 15.9
and males and females were equally represented. The
normal controls were of similar age and gender. Pul-
monary function testing data were not available for nor-
mal controls.
Pulmonary LFs were increased in patients with CF
LFs were quantified in lung tissue sections obtained
from patients with CF and normal controls. There was a
significant increase in the number of LFs in lung tissue
from patients with CF compared with controls (37.9 ±
7.4 total LFs/cm2 to 1.45 ± 0.7 total LFs/cm2) (Figs. 1a, b
and 2a). Consistent with the composition of LF, the
number of CD20+ cells was also significantly higher in
lung LF from patients with CF compared to controls
(373.6 ± 50.4 CD20+ B cells to 66.8 ± 10.7 CD20+ B cells)
(Figs. 1a, b and 2b). The number of B cells correlated
with the significantly larger and well-organized LFs in
CF subjects compared to controls (Fig. 2e). Of note, the
images obtained from CF subjects were taken at a higher
magnification as the LFs were too large to capture on
lower magnification (Fig. 1a). Please note size markers
on images. The control lung LFs were significantly
smaller and less organized (Fig. 1a and b). Figure 1b is a
composite image of an area of lung tissue at low magni-
fication that highlights the large number and size of LFs
in patients with CF. The clusters of CD20 staining in red
identify individual LFs. No statistically significant differ-
ences in follicle or B cell numbers were observed when
Pseudomonas aeruginosa (PSA)-colonized subjects were
compared to non-PSA colonized subjects or between pa-
tients with and without metabolic dysfunction.
LF B-cell BAFF and Ki67 expression is increased in human
CF lungs
Given the importance of BAFF in promoting B cell sur-
vival, maturation and augmenting the adaptive immune
response, BAFF expression in lung LFs in CF and con-
trols was also examined. BAFF expression was signifi-
cantly higher on LF B cells from patients with CF
compared to controls (298.9 ± 52.9 BAFF+ B cells to
43 ± 8.3 BAFF+ B cells) (Fig. 2c). The number of BAFF+
B cells correlated with the number of LF (Fig. 2f ) con-
sistent with increased B cell activation in CF. Ki67 is a
reliable proliferation marker and was used to identify B
cells in a proliferative state. There were a greater num-
ber of Ki67+ B cells in CF LF compared to controls
(29.66 ± 10.2 Ki67+ B cells to 0.3 ± 0.3 Ki67+ B cells)(Fig.
2d). There was a statistically significant correlation be-
tween BAFF and Ki67 expression (data not shown). To-
gether these findings suggest lung LF B cells in CF have
increased proliferative capacity and ability to augment B
cell responses.
LF with organized germinal centers correlated with LF
numbers in human CF lungs
One striking feature of many of the LF in patients with
CF was the presence of well-developed germinal centers
with centroblasts. No similar areas were observed in the
normal controls. The percentage of LF with organized
germinal centers correlated with LF numbers (Fig. 2g).
Lung LFs are increased in uninfected Cftr−/− lungs
Pulmonary LFs were quantified in uninfected Cftr−/− mice
and wild type controls. There was a statistically significant
increase in the number of lung LFs in Cftr−/− compared to
wild type control (2.04 ± 0.4 LFs/cm2 to 0 ± 0.0 LFs/cm2) in
the first Cftr−/− cohort housed at Brigham and Women’s
Hospital (Fig. 3a and b). Given the potential role for micro-
environmental, housing and microbiome influences to alter
lung immune development, we examined a second cohort
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of uninfected Cftr−/− mice bred and housed at a different
facility, Case Western University. We observed a similar
statistically significant increase in lung LF in uninfected
Cftr−/− mice compared to wild type (7.67 ± 1.8 LFs/cm2 to
0.57 ± 0.57 LFs/cm2)(Fig. 4a and b).
LF B-cell BAFF and CXCR4 expression is increased in
uninfected Cftr−/− lungs
Despite the absence of an exogenous infectious stimu-
lus, lung LF B cells from Cftr−/− mice had significantly
increased BAFF expression. There was essentially no
BAFF expression on wild type lung LF B cells (Fig. 3a
and d). These findings were validated in the second un-
infected Cftr−/− murine cohort (Fig. 4a). CXCR4 is a
critical chemokine receptor in B cell development.
CXCR4 B cell expression is dynamically regulated dur-
ing B cell maturation [24, 25]. CXCR4 is also an im-
portant centroblast marker in both humans and mice
[25]. There was a significant increase in CXCR4 stain-
ing throughout the lung LFs in Cftr−/− mice compared
to wild type (Fig. 4a). In wild type mice, CXCR4 stain-
ing was clustered to an area of the LF and was less in-
tense (Fig. 4a). Immunoglobulin G (IgG) staining was
also performed and was significantly increased in un-
infected Cftr−/− LF B cells (Fig. 3e). The intensity of
IgG staining correlated with intensity of BAFF stain-
ing as was demonstrated by triple staining (Fig. 3a,
merge panel).
MHC class II expression is increased in lung B cells from
Cftr−/− mice
Lung and splenic B cells were also analyzed by flow cy-
tometry. One lung from each mouse was disaggregated
and digested to release mononuclear cells that were
stained with directly conjugated antibodies. No differ-
ences in the percentage of B, CD4 or CD8 T cell cells
Fig. 1 Lung lymphoid follicles, B cells, BAFF+ and Ki67+ B cells were increased in CF patients. a Representative confocal images of triple-color
immunofluorescence staining of representative pulmonary lymphoid follicles (LFs) from subjects with CF (top panels) and normal controls (Ctrl,
bottom panels). B cells are identified by staining with red fluorophore for CD20. BAFF is identified by staining with green fluorophore. Ki67
positive cells have a gray color. 4′6-diamidino-2-phenylindole (blue) was used to counterstain the nuclei. The final panel in each row is a merged
file of CD20, BAFF and Ki67 staining. In the CF images (top row), the magnification is 20X. In the control images (bottom row), the magnification
is 60X. However, for the control images digital zooming was used to better visualize the CD20+ cells. The images shown are representative of LFs
in CF subjects (n = 27) and normal controls (n = 10). b Representative low power images of lung tissue from a subject with CF (left panel) and
normal control (right panel). Lymphoid follicles are identified by staining with red fluorophore for CD20. 4′6-diamidino-2-phenylindole (blue) was
used to counterstain the nuclei
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were observed between Cftr−/− lung and spleen com-
pared to wild type controls (data not shown). This is
consistent with prior publication of B and T lymphocyte
subsets in Cftr−/− mice on C57BL/6 background [26]. B
cell activation was assessed by staining with CD86 and
major histocompatibility complex class II (MHC class II)
. There were no differences in CD86 costimulatory cell
marker expression between Cftr−/− and wild type B cells
from either lung or spleen (data not shown). However,
there was a statistically significant increase in MHC class
II expression on Cftr−/− lung B cells compared to con-
trols (Fig. 5a and b). There was no significant difference
in MHC class II expression on splenic B cells (Fig. 5c).
B cells isolated from Cftr−/− mice have increased IL-6
production in response to LPS
Murine splenocyte B cells were stimulated with media or
LPS for 48 h. Supernatants were harvested and IL-6 and
IL-10 levels determined by ELISA. Inflammatory cytokines
were produced upon stimulation with LPS. Cftr−/− B cells
produced significantly more IL-6 in response to LPS
stimulation then wild type controls (Fig. 5d). Neither wild
type nor Cftr−/− mice produced IL-6 in the absence of LPS
stimulation. There was no significant IL-10 production
from either Cftr−/− or wild type control B cells in response
to the above conditions (wild type: 298.8 pg/ml-media
control, 274.2 pg/ml-LPS; Cftr−/−: 284.4 pg/ml-media con-
trol, 289.5 pg/ml-LPS).
LF B-cell TLR4 expression is increased in human CF lungs
One potential mechanism by which CFTR deficiency
could alter B cell function is through interactions with
other molecules such as TLR4 that can interact with many
cellular pathways and has been shown to interact synergis-
tically with BAFF [27]. CFTR has also been linked to
TLR4 signaling in macrophages [28]. TLR4 is not consti-
tutively expressed on human B cells. However, it has been
shown to be upregulated in inflammatory states [29].
TLR4 expression in lung LFs in CF and controls was ex-
amined. TLR4 expression was significantly higher on LF B
cells from patients with CF compared to controls
(10.8% ± 10.5 TLR4+ B cells to 0.49% ± 0.61 TLR4+ B cells)
(Fig. 6). These findings suggest lung LF B cells in CF ex-
press TLR4 that may amplify responses to bacterial patho-
gens and promote B cell dysregulation.
Discussion
CFTR deficiency on epithelial cells drives alterations in
airway biology that promote infection and ineffective air-
way clearance that lead to the progressive loss of lung
Fig. 2 B cells and BAFF+ and Ki67+ B cells were increased in patients with CF. The number of a lymphoid follicles, b B cells, c BAFF+ and d Ki67+
B cells were quantified in lung tissue from CF subjects (n = 27) and normal controls (n = 10). There was significant increase in LFs, B cells identified
by CD20 staining, BAFF+ and Ki67+ B cells in subjects with CF compared to controls. B cells, BAFF+ B cells and lymphoid follicles (LFs) with
organized germinal centers strongly correlated with total LFs. There was a significant correlation between the number of lymphoid follicles and e
CD20-positive B cells (R2 = 0.411, p = 0.006), f BAFF-positive B cells (R2 = 0.498, p < 0.0001) and g LFs with organized germinal centers (R2 = 0.497,
p < 0.0001) in patients with CF. This is a quantitative assessment of the data demonstrated in the representative images in Fig. 1. Mann-Whitney U
test was used to perform the statistical analysis (a-d). Box plots show the median values and 25th and 75th percentiles, and error bars show the
10th and 90th percentiles. Squares in (a) indicate outliers. Correlation coefficients were calculated using the Pearson rank method. A total of 27
CF subjects were analyzed. *p≤ 0.05; **p≤ 0.001; ***p≤ 0.0001, CF versus normal controls
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Fig. 4 LFs, B cells, BAFF+ and CXCR4+ B cells were increased in uninfected Cftr −/− mice. A second cohort of uninfected Cftr −/− mice bred,
housed and maintained at a different facility were also analyzed (cohort 2). a Representative confocal images of triple-color immunofluorescence
staining of representative pulmonary LFs from Cftr −/− mice (top row) and wild type (WT) controls (bottom row). B cells are identified by staining
for CD20 and red fluorophore. BAFF positive B cells were identified by staining with green fluorophore. CXCR4 positive B cells have a grey color.
4′6-diamidino-2-phenylindole (blue) was used to counterstain the nuclei. The final panel in each row is a merged file of CD20, BAFF and CXCR4
staining. In both the WT and Cftr −/− images the magnification is 60X. The images shown are representative of LFs in Cftr −/− mice (n = 8) and WT
controls (n = 4). Cftr −/− and WT lung b Lymphoid follicles and c B cells were quantified. Mann-Whitney U test was used to perform the statistical
analysis (b-c). Box plots show the median values and 25th and 75th percentiles, and error bars show the 10th and 90th percentiles. **p≤ 0.005,
Cftr −/− mice versus WT
Fig. 3 LFs, B cells, BAFF+ and IgG+ B cells were increased in uninfected Cftr −/− mice. a Representative confocal images of triple-color
immunofluorescence staining of representative pulmonary LFs from uninfected Cftr −/− mice (top two rows) and wild type (WT) controls (bottom
row) from cohort 1. B cells are identified by staining for CD45R and red fluorophore. BAFF positive cells have a grey color. IgG positive B cells
were identified by staining with green fluorophore. 4′6-diamidino-2-phenylindole (blue) was used to counterstain the nuclei. The final panel in
each row is a merged file of CD45R, BAFF and IgG staining. In the Cftr −/− mice images (top row), the magnification is 60X. In the wild type
control images (bottom row), the magnification is 100X. The images shown are representative of LFs in Cftr −/− mice (n = 6) and WT controls (n =
7). Cftr −/− and WT lung b Lymphoid follicles, c B cells, d BAFF+ B cells and e IgG+ B cells were quantified. Mann-Whitney U test was used to
perform the statistical analysis (b-e). Box plots show the median values and 25th and 75th percentiles, and error bars show the 10th and 90th
percentiles. *p≤ 0.05, **p≤ 0.001, Cftr −/− mice versus WT
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function in patients with CF. Patients with identical clin-
ical characteristics and CFTR mutations can have very
disparate outcomes. Individual differences in immune
responses and maintenance of homeostasis may play a
critical role in disease progression and morbidity, inde-
pendent of CFTR deficiency. However, the findings pre-
sented here and prior work in other cell types points to
a direct role for CFTR deficiency on immune function in
CF that may alter clinical outcomes.
Tertiary LFs can develop in the setting of chronic in-
flammation and/or infection [30, 31]. Lung tissue from pa-
tients with CF had numerous tertiary LFs, significantly
more than the controls. The majority of the LFs were well
organized with well-defined germinal centers (Fig. 1a and
b). In contrast to secondary lymphoid organs, tertiary LFs
are not encapsulated and are directly exposed to local
stimuli, antigens and inflammatory cytokines [30]. The
proximity of these LFs to infectious pathogens may facili-
tate protective immune responses. However, in the case of
CF where patients are chronically infected with bacteria
that are not eradicated by antibiotics, their proximity may
also lead to a feedback loop of inflammatory mediators,
leukocyte recruitment and immune activation, which in
turn could promote aberrant immune responses.
It is challenging in the setting of chronic infection to
tease out what aspects of altered lung immunity are a
direct effect of CFTR deficiency and which are driven by
chronic infection and immune activation. Prior work has
observed lung LF development in wild type mice in-
fected with P. aeruginosa [17]. In order to determine the
role of CFTR in the development of tertiary LFs and B
cell responses, lung tissue from uninfected Cftr −/− and
wild type mice was examined here. Lung tissue from un-
infected Cftr −/− mice had a significantly higher number
of LFs compared to wild type controls (Fig. 3a and b).
To validate these findings, a second cohort of mice was
obtained from a collaborator at a different institution ex-
posed to a different microenvironment and microbiome.
We observed a similar increase in the number of pul-
monary LFs in uninfected Cftr −/− mice compared to
controls (Fig. 4a and b). Despite the fact that the Cftr −/−
mouse does not recapitulate the phenotype of lung dis-
ease observed in humans, there have been reports in the
literature of changes in the lungs of uninfected Cftr −/−
mice including lung inflammatory cell infiltration [19,
20]. Interestingly, the observations were made in mice
that were 16 to 24 weeks of age and in the case of Kent,
G. et al., were age dependent. It is possible that
Fig. 5 Cftr −/− B cells have increased MHC class II and increased IL-6 response to LPSMHC class II expression was measured on B cells from lung
mononuclear cells a isolated from uninfected Cftr−/− and wild type controls with directly conjugated antibodies by flow cytometry. b A
representative histogram of MHC class II expression on lung B cells from uninfected Cftr −/− mice (gray histogram) and wild type controls (white
histogram). Isotype control staining is represented by dotted line. MHC class II expression was also measured on B cell splenocytes isolated from
uninfected Cftr −/− mice and wild type controls (c). d IL-6 production from B cells isolated from the spleens of Cftr −/− (n = 7) and WT mice (n = 4)
stimulated with media or lipopolysaccharide (LPS) for 48 h was determined. The concentration of IL-6 in supernatants was determined by ELISA.
Box plots show the median values and 25th and 75th percentiles, and error bars show the 10th and 90th percentiles. *p≤ 0.05, Cftr −/− mice
versus WT.
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organized LFs make take time to develop in the absence
of infection in Cftr −/− mice.
The potential important role for age in the development
of lymphoid follicle development is also highlighted by the
higher number of follicles in the older cohort (cohort 2)
compared to cohort 1 (Figs. 3b and 4b). However, differ-
ences in environmental or microbiome exposures between
the cohorts cannot be excluded. Intestinal isolated lymph-
oid follicle development has also been shown to signifi-
cantly increase with age [32]. As patients with cystic
fibrosis achieve longer lifespans, the cumulative effect of
immune dysfunction superimposed on the age-related im-
mune senescence may play a role in disease progression.
One of the likely drivers of LF development in the
lung is BAFF as has been previously shown in COPD
[13]. We observed a marked increase in BAFF expres-
sion in uninfected Cftr −/− lung LF B cells (Figs. 3a, d
and 4a), which may contribute to B cell survival and
may drive other autocrine and paracrine effects [12].
BAFF and tertiary lung lymphoid structures have been
shown to have detrimental effects. This was demon-
strated in a murine model of COPD where BAFF was
blocked by soluble BAFF fusion protein. In addition to
reduced inflammation and the prevention of LF develop-
ment, there was a significant reduction in alveolar wall
destruction [33]. Depletion of BAFF in Cftr −/− mice
prior to infection with P. aeruginosa depleted B cells and
impaired antimicrobial immunity. The mice were eutha-
nized 3 days after infection. LF development was not ex-
amined in this study that highlights the importance of
effective humoral immunity in CF [15]. However, aber-
rant or excessive BAFF expression could amplify inflam-
mation with deleterious effects. The fact that B cell
BAFF and Ki67 expression was increased in lung LFs
that were also increased in number in uninfected Cftr
−/− mice suggests a direct role for CFTR deficiency in in-
creased BAFF expression, B cell activation and the pro-
motion of LF development.
To further characterize the effects of CFTR deficiency
on B cell phenotype and function, lung and splenic B
cells from Cftr −/− mice were analyzed by flow cytometry
and stimulated in vitro. There were no differences in
costimulatory molecule expression or the percentage of
B cells. However, there was a statistically significant in-
crease in MHC class II expression on Cftr −/− lung B
cells compared to wild type (Fig. 5a and b). MHC class
Fig. 6 TLR4+ B cells are increased in patients with CF. a Representative confocal images of triple-color immunofluorescence staining of
representative pulmonary lymphoid follicles (LFs) from subjects with CF (bottom panels) and normal controls (top panels). B cells are identified by
staining with red fluorophore for CD20. TLR4 is identified by staining with green fluorophore. 4′6-diamidino-2-phenylindole (blue) was used to
counterstain the nuclei. The final panel in each row is a merged file of CD20, TLR4 and DAPI staining. The percentage of TLR4+ B cells was
quantified in lung tissue from CF subjects (n = 7) and normal controls (n = 5). There was significant increase in TLR4+ B cells in subjects with CF
compared to controls (b). Images were taken at 10X using a Nikon Eclipse 80i microscope. Mann-Whitney U test was used to perform the
statistical analysis. Box plots show the median values and 25th and 75th percentiles, and error bars show the 10th and 90th percentiles. *p =
0.003, CF versus normal controls
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II expression on B cells is critical for antigen presenta-
tion. In the presence of large amounts of antigen, B cells
in tertiary LFs could present antigen to other lympho-
cytes, which may be further amplified by increased
MHC class II expression [30]. It will remain to be deter-
mined if the increase in MHC class II expression is an
indirect consequence of an increase in the activation
state of B cells in Cftr −/− mice or if CFTR deficiency
plays a direct role in regulating MHC class II expression.
In vitro, Cftr −/− splenic B cells produced more IL-6
when stimulated with LPS than wild type controls (Fig.
5d). IL-6 has been shown to promote lung LF develop-
ment [34]. Augmented IL-6 inflammatory responses to
chronic airway infection may be an important mechan-
ism that amplifies LF formation in CF and may work
synergistically with BAFF that is increased in lung LF B
cells from uninfected Cftr −/− mice. Increased IL-6
mRNA was observed in bronchoalveolar lavage cells
stimulated with LPS from mice deficient in myeloid
lineage CFTR [5], which suggests altered cytokine re-
sponses and IL-6 production may be present in other
cell lineages in the absence of CFTR. These data suggest
an important role for CFTR promoting a pro-
inflammatory B cell phenotype, which in turn could pro-
mote tertiary LF formation.
Uninfected Cftr −/− lung LF B cells also had significantly
increased levels of CXCR4. CXCR4 is dynamically regu-
lated during B cell maturation and plays an important role
germinal center organization [24, 25]. CXCR4 responds to
its ligand CXCL12 and its expression helps distinguish
centroblasts from centrocytes. BAFF has not been re-
ported to alter CXCR4 expression [35]. Whether increased
CXCR4 expression in CFTR deficiency reflects an altered
B cell maturation state and/or if it alters the ability of B
cells to respond to germinal center chemokine gradients is
unclear. These findings, in addition to increased lung B
cell MHC class II expression, increased lung B cell BAFF
and Ki67 expression, and increased inflammatory cytokine
production upon activation raise concern for dysregulated
immune responses to chronic infection and for the loss of
immune tolerance to self-antigens that could lead to auto-
immunity. Elevated autoantibody levels have been linked
to lung disease severity in patients with CF [36, 37]. In
addition, several systemic autoimmune disorders are also
associated with CF including CF arthropathy [38–40] and
cutaneous vasculitis [41].
The mechanisms by which CFTR-deficiency alters im-
mune function in B cells have yet to be delineated. B cell
chloride conductance is altered in CFTR deficiency [10,
11]. It has been postulated that altered lymphocyte chloride
conductance could alter membrane potential and in turn
calcium flux. T lymphocyte intracellular calcium flux has
been shown to be increased in CFTR deficient T cells upon
stimulation. Increased nuclear factor of activated T-cells
(NFAT) nuclear translocation, which is modulated by
calcium-associated signaling pathways, was observed in Cftr
−/− T cells upon activation resulting in increased inflamma-
tory cytokine production [8].
Interactions between CFTR and other molecules im-
portant in immune activation may also be important.
Activated CFTR deficient macrophages have reduced
ezrin protein levels and altered localization [28]. Ezrin
is a member of the ezrin-radixin-moesin family that
bridges plasma membrane proteins to the actin cyto-
skeleton and regulates cellular processes that require
membrane remodeling and modulate signaling events.
Decreased ezrin levels were linked to reduced PI3K/
AKT signaling upon TLR4 activation in CFTR defi-
cient macrophages and promoted a pro-inflammatory
phenotype [28]. Ezrin has also be shown to maintain
the topology of signaling molecules in the immuno-
logic synapse and to down regulate Erk1/2 and NFAT
signaling [42] in T lymphocytes. Ezrin plays a critical
role in regulating B cell receptor signaling and lipid
raft aggregation. Loss of ezrin increases B cell activa-
tion and increased MHC class II expression [42]. Re-
duced ezrin levels, as have been observed in CFTR
deficient macrophages, may alter the function of the
immunologic synapse and downstream signaling con-
tributing to pro-inflammatory responses in CFTR de-
ficient B cells as well. The role of these mechanisms
in CFTR deficient B cells and their importance in the
pathogenesis of CF remains to be defined.
In light of the chronic airway exposure to bacterial patho-
gens that occurs in cystic fibrosis, the expression of patho-
gen sensing molecules is likely an important contributor to
immune activation. CFTR-dependent aberrant TLR4 traf-
ficking has been observed in CFTR deficient macrophages,
which promoted a hyperinflammatory response [4, 28]. B
cell TLR4 expression was examined in CF subjects and
controls. In contrast to mice, humans B cells do not consti-
tutively express TLR4. However, human B cells have been
shown to upregulate TLR4 in response to inflammatory
stimuli [29]. As expected, based on literature, there was
scant expression of TLR4 in lung B cells from control sub-
jects. There was a significantly higher number of TLR4+ B
cells in CF subjects (Fig. 6). Increased B cell TLR4 expres-
sion may amplify cytokine production as has been shown
in macrophages. TLR4 expression can also contribute to B
cell maturation. Interestingly, BAFF and TLR4, both of
which had significantly increased expression in lung B cells
in CF subjects, have been previously shown to have a syner-
gistic effect on B cell maturation [27]. Additional studies
will be needed to dissect the complex mechanisms that
promote B cell dysregulation and lymphoid follicle forma-
tion in cystic fibrosis.
The limitations of this study include the fact that with
few exceptions human tissue samples studied were from
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patients with severe lung disease. Lung biopsies are in-
frequently performed in patients with CF, so correlation
of immunohistochemical findings with FEV1 and other
clinical parameters over a spectrum of disease was not
possible. Given that Cftr −/− mice do not develop the air-
way pathology observed in patients with cystic fibrosis,
the effects of CFTR deficiency on B cell function and ac-
tivation observed in murine analyses may be more pro-
nounced or altered in human disease. We did not
examine the ability of Cftr −/− B cells to promote
humoral immunity and host defense as it was beyond
the scope of this study. We also did not examine the di-
verse B cell subsets found in LFs and germinal centers.
It is possible that CFTR deficiency may play a more
prominent role in specific B cell maturation subsets. In
addition, since archival lung tissue from patients with
CF was used, correlation of immunohistochemical find-
ings with B cell functional assays using peripheral blood
B cells from patients with CF and controls could not be
performed.
The data presented here point to an important role for
B cells and tertiary LF development in CFTR-mediated
immune activation and the pathobiology of lung disease
in CF. Although we did not examine other organs typic-
ally affected by CF such as the gastrointestinal system, it
is possible that altered B cell responses in CF could
affect other sites of disease. Immune dysregulation may
be an important contributor to the pathobiology of CF
where chronic airway infection may augment the effects
of CFTR-mediated immune dysfunction. There may be a
clinical role for immunomodulation in altering CF out-
comes. Finding biomarkers that identify immune dysreg-
ulation and identifying precise pharmacologic targets
that can alter disease progression in CF merit further
investigation.
Conclusion
The CF transmembrane conductance regulator (CFTR)
plays a direct role in promoting tertiary lung LF develop-
ment, B cell activation and B cell inflammatory cytokine
production in the absence of infection.
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